T
Thomas Doerr
Researcher at Celgene
Publications - 11
Citations - 68
Thomas Doerr is an academic researcher from Celgene. The author has contributed to research in topics: Pomalidomide & Medicine. The author has an hindex of 5, co-authored 6 publications receiving 64 citations.
Papers
More filters
Journal ArticleDOI
MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment
Jeffrey Matous,David S. Siegel,Sagar Lonial,R. Donald Harvey,Claudia Kasserra,Yan Li,Min Chen,Thomas Doerr,Lars Sternas,Mohamed H. Zaki,Christian Jacques,Jatin J. Shah +11 more
TL;DR: POM + low-dose dexamethasone (LoDEX) has shown efficacy in pts with relapsed/refractory MM (RRMM) with moderate RI in phase 2 and phase 3 trials, however, pts with severe RI were excluded from these trials.
Journal ArticleDOI
Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
Paul G. Richardson,Albert Oriol Rocafiguera,Meral Beksac,Anna Marina Liberati,Monica Galli,Fredrik Schjesvold,Jindriska Lindsay,Katja Weisel,Darell White,Thierry Facon,Jesús F. San-Miguel,Kazutaka Sunami,Peter O'Gorman,Pieter Sonneveld,Xin Yu,Thomas Doerr,Amine Bensmaine,Mohamed H. Zaki,Kenneth C. Anderson,Meletios A. Dimopoulos +19 more
TL;DR: POM + DEX is indicated as a standard-of-care treatment in RRMM with demonstrated synergistic anti-myeloma activity with dexamethasone (DEX) and proteasome inhibitors (PIs).
Journal ArticleDOI
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial
Tatsuo Ichinohe,Yoshiaki Kuroda,Shinichiro Okamoto,Kosei Matsue,Shinsuke Iida,Kazutaka Sunami,Takuya Komeno,Kenshi Suzuki,Kiyoshi Ando,Masafumi Taniwaki,Kensei Tobinai,Takaaki Chou,Hitomi Kaneko,Hiromi Iwasaki,Chie Uemura,Hiromi Tamakoshi,Mohamed H. Zaki,Thomas Doerr,Shotaro Hagiwara +18 more
TL;DR: It is demonstrated that pomalidomide plus low-dose dexamethasone is an effective and safe treatment for Japanese patients with RRMM, although careful attention needs to be paid to serious infections.
Journal ArticleDOI
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
Kosei Matsue,Hiromi Iwasaki,Takaaki Chou,Kensei Tobinai,Kazutaka Sunami,Yoshiaki Ogawa,Mari Kurihara,Shuichi Midorikawa,Mohamed H. Zaki,Thomas Doerr,Shinsuke Iida +10 more
TL;DR: Efficacy outcomes with pomalidomide plus low‐dose dexamethasone were consistent with those of previous studies, and the most frequently occurring grade ≥3 adverse events were neutropenia, anemia, lymphopenia, and pneumonia, consistent with previous studies.
Journal ArticleDOI
MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
TL;DR: MM-007 is a global, multicenter, randomized, open-label Ph 3 trial designed to compare efficacy and safety of PVD vs VD in pts with RRMM.